CRBP (Corbus Pharmaceuticals Holdings) ROC %: -2,140.38% (As of Mar. 2026)


CRBP Corbus Pharmaceuticals Holdings Inc CRBP
32 GF Score
Price $8.69
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings ROC %?

Corbus Pharmaceuticals Holdings CRBP +5.81% 32 ROC % is -2,140.38% as of Mar. 2026. GuruFocus rates CRBP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Corbus Pharmaceuticals Holdings's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -2,140.38%.

As of today (2026-06-26), Corbus Pharmaceuticals Holdings's WACC % is 12.48%. Corbus Pharmaceuticals Holdings's ROC % is -1713.90% (calculated using TTM income statement data). Corbus Pharmaceuticals Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Corbus Pharmaceuticals Holdings's WACC % is 12.48%. Corbus Pharmaceuticals Holdings's ROC % is -1713.90% (calculated using TTM income statement data). Corbus Pharmaceuticals Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Corbus Pharmaceuticals Holdings ROC % Related Terms


Corbus Pharmaceuticals Holdings ROC % Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings ROC % Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -346.39 -247.09 -255.88 -333.75 -1,363.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,317.78 -1,389.59 -1,640.79 -1,485.19 -2,140.38
CRBP
32GF Score
Corbus Pharmaceuticals Holdings Inc CRBP
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings ROC % Calculation

Corbus Pharmaceuticals Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-85.31 * ( 1 - 0% )/( (6.785 + 5.733)/ 2 )
=-85.31/6.259
=-1,363.00 %

where

Corbus Pharmaceuticals Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-97.216 * ( 1 - 0% )/( (5.733 + 3.351)/ 2 )
=-97.216/4.542
=-2,140.38 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -2,140.38% mean?
Corbus Pharmaceuticals Holdings (CRBP) has a ROC % of -2,140.38% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' ROC % too high?
Corbus Pharmaceuticals Holdings' current ROC % is -2,140.38%. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' ROC % compare to AGEN and HURA?
Corbus Pharmaceuticals Holdings' ROC % of -2,140.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current ROC % is -2,140.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (CRBP) has a current ROC % of -2,140.38%. The current ROC % is -2,140.38%. Corbus Pharmaceuticals Holdings' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (CRBP), the current ROC % is -2,140.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges 0SZI:UK3371:Germany
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
32GF Score

Get the complete analysis for CRBP

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.69
Price